Efficacy and safety of emerging immunotherapies in psoriasis

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1  Nestle FO, Kaplan DH, Barker J. Psoriasis. N. Engl. J. Med.361(5),496–509 (2009).•• An authoritative overview summarizing the current understanding of the pathogenetic, molecular and immunologic basis of psoriasis.Crossref, Medline, CAS, Google Scholar
• 2  Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet370(9583),263–271 (2007).Crossref, Medline, CAS, Google Scholar
• 3  Hughes S, Williams SE, Turnberg LA. Crohn‘s disease and psoriasis. N. Engl. J. Med.308(2),101 (1983).Medline, CAS, Google Scholar
• 4  Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J. Am. Acad. Dermatol.41(3 Pt 1),401–407 (1999).Crossref, Medline, CAS, Google Scholar
• 5  Fry L, Baker BS, Powles AV, Fahlen A, Engstrand L. Is chronic plaque psoriasis triggered by microbiota in the skin? Br. J. Dermatol.169(1),47–52 (2013).Crossref, Medline, CAS, Google Scholar
• 6  Saurat JH, Stingl G, Dubertret L et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br. J. Dermatol.158(3),558–566 (2008).Crossref, Medline, CAS, Google Scholar
• 7  Laws P, Barton A, Warren RB. Psoriatic arthritis – what the dermatologist needs to know. J. Eur. Acad. Dermatol. Venereol.24(11),1270–1277 (2010).Crossref, Medline, CAS, Google Scholar
• 8  Kavanaugh A, Ritchlin C, Rahman P et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the Phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann. Rheum. Dis.73(6),1000–1006 (2014).Crossref, Medline, CAS, Google Scholar
• 9  Mcinnes IB, Kavanaugh A, Gottlieb AB et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the Phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet382(9894),780–789 (2013).Crossref, Medline, CAS, Google Scholar
• 10  Ryan C, Menter A, Warren RB. The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis. Mol. Diagn. Ther.14(2),81–93 (2010).Crossref, Medline, CAS, Google Scholar
• 11  Lowes MA, Kikuchi T, Fuentes-Duculan J et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J. Invest. Dermatol.128(5),1207–1211 (2008).Crossref, Medline, CAS, Google Scholar
• 12  Loesche C PF, Sinner F, Valentin M-A. Novel microperfusion method confirms that psoriasis lesional skin contains higher protein levels of IL-17A and β-defensin-2 comapred to nonlesional skin (abstract). J. Am. Acad. Dermatol.70,AB177 (2014).Google Scholar
• 13  Lewis BJ, Rajpara S, Haggart AM, Wilson HM, Barker RN, Ormerod AD. Predominance of activated, clonally expanded T helper type 17 cells within the CD4⁺ T cell population in psoriatic lesions. Clin. Exp. Immunol.173(1),38–46 (2013).Crossref, Medline, CAS, Google Scholar
• 14  Girolomoni G, Mrowietz U, Paul C. Psoriasis: rationale for targeting interleukin-17. Br. J. Dermatol.167(4),717–724 (2012).Crossref, Medline, CAS, Google Scholar
• 15  Puel A, Picard C, Cypowyj S, Lilic D, Abel L, Casanova JL. Inborn errors of mucocutaneous immunity to Candida albicans in humans: a role for IL-17 cytokines? Curr. Opin. Immunol.22(4),467–474 (2010).Crossref, Medline, CAS, Google Scholar
• 16  Puel A, Cypowyj S, Marodi L, Abel L, Picard C, Casanova JL. Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis. Curr. Opin. Allergy Clin. Immunol.12(6),616–622 (2012).Crossref, Medline, CAS, Google Scholar
• 17  Liu L, Okada S, Kong XF et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J. Exp. Med.208(8),1635–1648 (2011).Crossref, Medline, CAS, Google Scholar
• 18  Bockle BC, Wilhelm M, Muller H, Gotsch C, Sepp NT. Oral mucous squamous cell carcinoma-an anticipated consequence of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). J. Am. Acad. Dermatol.62(5),864–868 (2010).Crossref, Medline, Google Scholar
• 19  Umemura M, Yahagi A, Hamada S et al. IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection. J. Immunol.178(6),3786–3796 (2007).Crossref, Medline, CAS, Google Scholar
• 20  Gopal R, Lin Y, Obermajer N et al. IL-23-dependent IL-17 drives Th1-cell responses following Mycobacterium bovis BCG vaccination. Eur. J. Immunol.42(2),364–373 (2012).Crossref, Medline, CAS, Google Scholar
• 21  Hueber W, Sands BE, Lewitzky S et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn‘s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut61(12),1693–1700 (2012).Crossref, Medline, CAS, Google Scholar
• 22  Targan SR, Feagan BG, Vermeire SEA. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn‘s Disease (abstract). Gastroenterology143(3),e26 (2012).Crossref, Medline, CAS, Google Scholar
• 23  Colombel JF, Sendid B, Jouault T, Poulain D. Secukinumab failure in Crohn‘s disease: the yeast connection? Gut62(5),800–801 (2013).Crossref, Medline, CAS, Google Scholar
• 24  Hueber W, Patel DD, Dryja T et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Translat. Med.2(52),52ra72 (2010).Crossref, Medline, Google Scholar
• 25  Rich P, Sigurgeirsson B, Thaci D et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, Phase II regimen-finding study. Br. J. Dermatol.168(2),402–411 (2013).Crossref, Medline, CAS, Google Scholar
• 26  Papp KA, Langley RG, Sigurgeirsson B et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled Phase II dose-ranging study. Br. J. Dermatol.168(2),412–421 (2013).Crossref, Medline, CAS, Google Scholar
• 27  Langley RG, Elewski BE, Lebwohl M et al. Secukinumab in plaque psoriasis – results of two Phase 3 trials. N. Engl. J. Med.371(4),326–338 (2014).•• The most updated publication on the Phase III studies for secukinumab FIXTURE and ERASURE, the largest clinical trial reported on a IL-17 inhibitor to date, and the only current study reporting with a active comparator arm etanercept.Crossref, Medline, Google Scholar
• 28  Blauvelt A GA, Prinz J, Pathan R, Cooper S. Secukinumab efficacy and safety in subjects with moderate to severe plaque psoriasis: Results from the Judging the efficacy of secUkinumab in patients with psoriasis using autoiNjector: a Clinical Trial evalUating treatment Results Trial (JUNCTURE) (abstract). J. Am. Acad. Dermatol.70,AB185 (2014).Google Scholar
• 29  Warren R, Guettner A, Morita A, Gisondi P, Cooper S. Secukinumab efficacy in subjects with moderate to severe plaque psoriasis: pooled subgroup analyses by patient age of 4 Phase 3 clinical studies (abstract). J. Am. Acad. Dermatol.70,AB186 (2014).Google Scholar
• 30  Ward N, Guettner A, Sands B, Cooper S. Secukinumab safety and tolerability in subjects with moderate to severe plaque psoriasis: a pooled subgroup analysis of 10 clinical studies evaluating exacerbation of Crohn‘s disease (abstract). J. Am. Acad. Dermatol.70,AB188 (2014).Google Scholar
• 31  Krueger JG, Fretzin S, Suarez-Farinas M et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J. Allergy Clin. Immunol.130(1),145–154 e149 (2012).Crossref, Medline, CAS, Google Scholar
• 32  Leonardi C, Matheson R, Zachariae C et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med.366(13),1190–1199 (2012).• The first study into the efficacy of a novel IL-17 inhibitor ixekizumab for the treatment of chronic plaque psoriasis.Crossref, Medline, CAS, Google Scholar
• 33  Gordon KB, Leonardi C, Braun D et al. Results after at least 52 weeks of open label treatment with ixekizumab, an anti-IL-17A monoclonal antibody, in a Phase 2 study in chrnoic plaque psoriasis (abstract). J. Am. Acad. Dermatol.70,AB183 (2014).Google Scholar
• 34  Russell CB, Rand H, Bigler J et al. Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody. J. Immunol.192(8),3828–3836 (2014).Crossref, Medline, CAS, Google Scholar
• 35  Papp KA, Leonardi C, Menter A et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med.366(13),1181–1189 (2012).• The first study into the efficacy of a novel IL-17 inhibitor brodalumab for the treatment of chronic plaque psoriasis.Crossref, Medline, CAS, Google Scholar
• 36  Papp K, Menter A, Milmont C, Leonardi C, Ortonne JP, Klekotka P. Maintenance of clinical response with long-term brodalumab (AMG 827) therapy for psoriasis: Week 96 results from an open-label extension study (abstract). J. Am. Acad. Dermatol.70,AB174 (2014).Google Scholar
• 37  Mease PJ, Nirula A, Ritchlin C, Greenwald M, Genovese MC, Erondu N. Clinical response and improvement in psoriasis symptoms in subjects with psoriatic arthritis following treatment with brodalumab, an anti-IL-17R antibody (abstract). J. Am. Acad. Dermatol.S70,AB165 (2014).Google Scholar
• 38  Piskin G, Sylva-Steenland RM, Bos JD, Teunissen MB. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J. Immunol.176(3),1908–1915 (2006).CAS, Google Scholar
• 39  Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N. Engl. J. Med.361(9),888–898 (2009).•• A very useful article for an overview of the main scientific findings leading to the understanding of the role of IL-17 and Th17 cells, from mouse models, role in the response against infectious agents to the pathway as a therapeutic target in chronic inflammation.Crossref, Medline, CAS, Google Scholar
• 40  Sofen H, Smith S, Matheson RT et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J. Allergy Clin. Immunol.133(4),1032–1040 (2014).Crossref, Medline, CAS, Google Scholar
• 41  Murphy CA, Langrish CL, Chen Y et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med.198(12),1951–1957 (2003).Crossref, Medline, CAS, Google Scholar
• 42  Nair RP, Duffin KC, Helms C et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat. Genet.41(2),199–204 (2009).Crossref, Medline, CAS, Google Scholar
• 43  Hebert HL, Ali FR, Bowes J, Griffiths CE, Barton A, Warren RB. Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy. Br. J. Dermatol.166(3),474–482 (2012).Crossref, Medline, CAS, Google Scholar
• 44  Ryan C, Thrash B, Warren RB, Menter A. The use of ustekinumab in autoimmune disease. Exp. Opin. Biol. Ther.10(4),587–604 (2010).Crossref, Medline, CAS, Google Scholar
• 45  Gordon KB, Langley RG, Gottlieb AB et al. A Phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J. Invest. Dermatol.132(2),304–314 (2012).• The Phase III clinical trial on the efficacy of briakinumab in psoriasis, which raised concerns about the risk of major adverse cardiovascular events in p40 subunit inhibitors for IL-12/23.Crossref, Medline, CAS, Google Scholar
• 46  Kimball AB, Papp KA, Wasfi Y et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J. Eur. Acad. Dermatol. Venereol.27(12),1535–1545 (2013).Crossref, Medline, CAS, Google Scholar
• 47  Tzellos T, Kyrgidis A, Zouboulis CC. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J. Eur. Acad. Dermatol. Venereol.27(5),622–627 (2013).Crossref, Medline, CAS, Google Scholar
• 48  Ryan C, Leonardi CL, Krueger JG et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA306(8),864–871 (2011).Crossref, Medline, CAS, Google Scholar
• 49  Langley RG, Papp K, Gottlieb AB et al. Safety results from a pooled analysis of randomized, controlled Phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J. Eur. Acad. Dermatol. Venereol.27(10),1252–1261 (2013).Medline, CAS, Google Scholar
• 50  Callis-Duffin K, Gordon KB, Wasfi Y, Shen YK. A Phase 2 multicenter, randomized, placebo- and active-comparator-controlled, dose-ranging trial to evaluate guselkumab for the treatment of patients with moderate to severe plaque-type psoriasis (X-PLORE) (abstract). J. Am. Acad. Dermatol.70,AB162 (2014).Google Scholar
• 51  Reich K, Langley R, Papp K et al. Treatment with anti-IL-23p19 humanized monoclonal antibody (MK-3222) provides significant improvement in psoriasis that is maintained for up to 52 weeks (abstract). Presented at: 22nd Annual Congress of the European Academy of Dermatology and Venereology. Istanbul, Turkey, 2–6 October 2013.Google Scholar
• 52  Chang BY, Zhao F, He X et al. JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice. J. Immunol.183(3),2183–2192 (2009).Crossref, Medline, CAS, Google Scholar
• 53  Papp KA, Menter A, Strober B et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br. J. Dermatol.167(3),668–677 (2012).Crossref, Medline, CAS, Google Scholar
• 54  Bachelez H, Van De Kerkhof P, Comparison of tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a Phase 3 randomized trial. Presented at: The Annual Meeting of the American Academy of Dermatology. Denver, CO, USA, 21 March–25 March 2014.Google Scholar
• 55  Schafer PH, Parton A, Gandhi AK et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br. J. Pharmacol.159(4),842–855 (2010).Crossref, Medline, CAS, Google Scholar
• 56  Papp K, Cather JC, Rosoph L et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet380(9843),738–746 (2012).Crossref, Medline, CAS, Google Scholar
• 57  Papp K, Griffiths CE, Leonardi C et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: Results from the randomized treatment withdrawal phase of a Phase 3, randomized, controlled trial (ESTEEM 1) (abstract). J. Am. Acad. Dermatol.70,AB164 (2014).Google Scholar
• 58  Paul C, Crowley J, Cather JC et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a Phase 3, randomized, controlled trial (ESTEEM 2) (abstract). J. Am. Acad. Dermatol.70,AB164 (2014).Google Scholar
• 59  Kavanaugh A, Mease PJ, Gomez-Reino JJ et al. Treatment of psoriatic arthritis in a Phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann. Rheum. Dis.73(6),1020–1026 (2014).Crossref, Medline, CAS, Google Scholar
• 60  Mease PJ, Genovese MC, Greenwald MW et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N. Engl. J. Med.370(24),2295–2306 (2014).Crossref, Medline, Google Scholar
• 61  Mcinnes IB, Sieper J, Braun J et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, Phase II proof-of-concept trial. Ann. Rheum. Dis.73(2),349–356 (2014).Crossref, Medline, CAS, Google Scholar
• 62  Burden AD, Warren RB, Kleyn CE et al. The British Association of Dermatologists‘ Biologic Interventions Register (BADBIR): design, methodology and objectives. Br. J. Dermatol.166(3),545–554 (2012).• Registries are vital to assess the long-term safety of drugs outside of a clinical trial setting. The British Association of Dermatologists‘ Biologic Interventions Register (BADBIR), which design is outlined in this paper, is an example of a high-quality, multicentre national registry aimed to answer some of the questions posed by this review.Crossref, Medline, CAS, Google Scholar
• 63  Jani M, Barton A, Warren RB, Griffiths CE, Chinoy H. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology53(2),213–222 (2014).Crossref, Medline, CAS, Google Scholar
• 64  Papp KA, Kaufmann R, Thaçi D. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a Phase II,multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J. Eur. Acad. Dermatol. Venereol.27(3),e376–e383 (2013).Crossref, Medline, CAS, Google Scholar